Teligent Inc. (TLGT) Trading 2.4% Higher
Teligent Inc. (NASDAQ:TLGT) shares traded up 2.4% on Thursday . The company traded as high as $7.86 and last traded at $7.81, with a volume of 339,860 shares trading hands. The stock had previously closed at $7.63.
TLGT has been the topic of several recent analyst reports. JMP Securities initiated coverage on Teligent in a research note on Wednesday, June 29th. They set a “hold” rating on the stock. Zacks Investment Research downgraded Teligent from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. TheStreet upgraded Teligent from a “sell” rating to a “hold” rating in a research note on Thursday, June 23rd. Finally, Raymond James Financial Inc. initiated coverage on Teligent in a research note on Wednesday, June 22nd. They set a “strong-buy” rating and a $11.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $9.42.
The stock’s market cap is $414.14 million. The stock has a 50-day moving average price of $8.15 and a 200-day moving average price of $6.38.
Teligent (NASDAQ:TLGT) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04. The firm earned $17.14 million during the quarter, compared to analysts’ expectations of $16.03 million. During the same quarter in the previous year, the firm posted ($0.05) EPS. The firm’s revenue for the quarter was up 92.8% on a year-over-year basis. Analysts predict that Teligent Inc. will post $0.05 earnings per share for the current year.
Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.